Literature DB >> 1164050

Activity of rifampicin on Mycobacterium ulcerans.

A Havel, S R Pattyn.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1975        PMID： 1164050

Source DB:  PubMed          Journal:  Ann Soc Belg Med Trop        ISSN： 0772-4128


× No keyword cloud information.
  10 in total

Review 1.  Treating Mycobacterium ulcerans disease (Buruli ulcer): from surgery to antibiotics, is the pill mightier than the knife?

Authors:  Paul J Converse; Eric L Nuermberger; Deepak V Almeida; Jacques H Grosset
Journal:  Future Microbiol       Date:  2011-10       Impact factor: 3.165

2.  Efficacy of the combination rifampin-streptomycin in preventing growth of Mycobacterium ulcerans in early lesions of Buruli ulcer in humans.

Authors:  S Etuaful; B Carbonnelle; J Grosset; S Lucas; C Horsfield; R Phillips; M Evans; D Ofori-Adjei; E Klustse; J Owusu-Boateng; G K Amedofu; P Awuah; E Ampadu; G Amofah; K Asiedu; M Wansbrough-Jones
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

3.  Activities of several antimicrobials against Mycobacterium ulcerans infection in mice.

Authors:  H Dega; J Robert; P Bonnafous; V Jarlier; J Grosset
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

4.  Clinical efficacy of combination of rifampin and streptomycin for treatment of Mycobacterium ulcerans disease.

Authors:  Fred Stephen Sarfo; Richard Phillips; Kingsley Asiedu; Edwin Ampadu; Nana Bobi; E Adentwe; Awuli Lartey; Ishmael Tetteh; M Wansbrough-Jones
Journal:  Antimicrob Agents Chemother       Date:  2010-06-21       Impact factor: 5.191

5.  Drug Efficacy Testing in the Mouse Footpad Model of Buruli Ulcer.

Authors:  Paul J Converse; Deepak V Almeida; Eric L Nuermberger
Journal:  Methods Mol Biol       Date:  2022

6.  In vitro susceptibility of Mycobacterium ulcerans to clarithromycin.

Authors:  F Portaels; H Traore; K De Ridder; W M Meyers
Journal:  Antimicrob Agents Chemother       Date:  1998-08       Impact factor: 5.191

7.  Isolation of three Mycobacterium ulcerans strains resistant to rifampin after experimental chemotherapy of mice.

Authors:  Laurent Marsollier; Nadine Honoré; Pierre Legras; Anne Lise Manceau; Henri Kouakou; Bernard Carbonnelle; Stewart T Cole
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191

Review 8.  Clinical efficacy of Rifampicin and Streptomycin in combination against Mycobacterium ulcerans infection: a systematic review.

Authors:  Marius Zambou Vouking; Violette Claire Tamo; Carine Nouboudem Tadenfok
Journal:  Pan Afr Med J       Date:  2013-08-29

9.  Clinical and bacteriological efficacy of rifampin-streptomycin combination for two weeks followed by rifampin and clarithromycin for six weeks for treatment of Mycobacterium ulcerans disease.

Authors:  Richard O Phillips; Fred S Sarfo; Mohammed K Abass; Justice Abotsi; Tuah Wilson; Mark Forson; Yaw A Amoako; William Thompson; Kingsley Asiedu; Mark Wansbrough-Jones
Journal:  Antimicrob Agents Chemother       Date:  2013-12-09       Impact factor: 5.191

10.  Triple oral beta-lactam containing therapy for Buruli ulcer treatment shortening.

Authors:  María Pilar Arenaz-Callao; Rubén González Del Río; Ainhoa Lucía Quintana; Charles J Thompson; Alfonso Mendoza-Losana; Santiago Ramón-García
Journal:  PLoS Negl Trop Dis       Date:  2019-01-28
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.